Home Cart Sign in  
Chemical Structure| 1310422-41-3 Chemical Structure| 1310422-41-3

Structure of SEP-363856 HCl
CAS No.: 1310422-41-3

Chemical Structure| 1310422-41-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Synonyms: SEP-856 hydrochloride; Ulotaront

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SEP-363856 HCl

CAS No. :1310422-41-3
Formula : C9H14ClNOS
M.W : 219.73
SMILES Code : CNC[C@H]1C2=C(C=CS2)CCO1.[H]Cl
Synonyms :
SEP-856 hydrochloride; Ulotaront
MDL No. :MFCD32701938

Safety of SEP-363856 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362

Related Pathways of SEP-363856 HCl

GPCR

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
ICR mice Forced swimming test (FST), tail suspension test (TST), chronic unpredictable mild stress (CUMS) model Oral 0.1, 0.3, 1, 3, 10, 15 mg/kg Single administration or 21-day continuous administration To evaluate the antidepressant-like effects of SEP-363856 alone or in combination with duloxetine. Results showed that SEP-856 exhibited antidepressant-like effects in FST and TST, especially at doses of 0.3, 1, and 10 mg/kg. Compared with duloxetine alone, the combination of duloxetine and SEP-856 produced more significant antidepressant-like effects in FST and TST. In the CUMS model, both SEP-856 and duloxetine alone or in combination reversed the CUMS-induced reduction in sucrose preference. Molecules. 2022 Apr 25;27(9):2755
Rats Healthy rats Oral 1, 3 or 10 mg/kg Single dose Evaluate the ability of SEP-856 to modulate the activity of specific brain regions under basal conditions Int J Mol Sci. 2021 Apr 16;22(8):4119
ICR mice Schizophrenia models Oral 1, 3, 10 mg/kg Single administration To evaluate the antipsychotic effects of SEP-363856 in combination with olanzapine in the apomorphine (APO)-induced climbing test Molecules. 2022 Apr 14;27(8):2550
Mice Drd1a-tdTomato mice and C57BL/6J mice Bath application 10 μM and 30 μM 15 minutes To evaluate the effect of ulotaront on spontaneous neuronal firing and excitatory synaptic transmission in hippocampal CA1, results showed that ulotaront reduced spontaneous neuronal firing and enhanced excitatory synaptic transmission. Neuropsychopharmacology. 2024 Jun;49(7):1091-1103
Human Patients with schizophrenia Oral 25/50/75 mg/d Once daily for 26 weeks To evaluate the long-term safety and effectiveness of ulotaront in patients with schizophrenia. Results showed minimal changes in body weight, cholesterol, triglycerides, and prolactin, with no extrapyramidal effects. Significant improvements were observed in PANSS total score and CGI-S score. NPJ Schizophr. 2021 Dec 9;7(1):63
Mice C57BL/6 wild-type mice Intraperitoneal injection 3 mg/kg Single administration To test the effect of SEP-363856 on reversing the ketamine-induced increase in striatal dopamine synthesis capacity. Results showed that SEP-363856 significantly reduced the ketamine-induced increase in dopamine synthesis capacity. Mol Psychiatry. 2021 Jun;26(6):2562-2576
Humans Patients with schizophrenia and healthy volunteers Oral 5–150 mg/day Once daily for 7 days To evaluate the population pharmacokinetics (PopPKs) of ulotaront in adult subjects and characterize potential pharmacokinetic covariates. Results showed that ulotaront exhibited dose-proportionality in doses ranging from 10 to 100 mg, was well-absorbed, and had moderate interindividual variability. CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1245-1254

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.55mL

0.91mL

0.46mL

22.76mL

4.55mL

2.28mL

45.51mL

9.10mL

4.55mL

 

Historical Records

Categories